Alzheimer’s breakthrough drugs show little to no benefit review finds…

A complete analysis of supposedly revolutionary Alzheimer’s medicines has shown they supply minimal benefit to sufferers.

This disheartening conclusion comes from an examination of scientific trials focusing on people with gentle cognitive impairment or gentle dementia. Scientists found that anti-amyloid medicines had “trivial” results on cognition and dementia severity across 18 months, with enhancements in daily functioning rated as “small at best”.

These outcomes characterize a setback for rising therapies aimed at slowing Alzheimer’s development by eliminating amyloid protein clusters that accumulate in the mind. Amyloid plaques represent a elementary attribute of Alzheimer’s disease, alongside tau protein, which creates dangerous tangles within neurons.

Recent findings on anti-amyloid medicines

Anti-amyloid medicines have been hailed as transformative when scientific trials confirmed modest yet measurable enhancements in dementia sufferers.

Nevertheless, the Cochrane review decided that both donanemab and lecanemab fall short of their promised effectiveness for gentle cognitive impairment or gentle dementia instances.

“Amyloid‐beta‐targeting monoclonal antibodies probably result in little to no difference in functional ability as measured on the ‘ADCS‐ADL’ (Alzheimer’s Disease Cooperative Study – Activities of Daily Living) scale,” the researchers famous in the review.

The review’s authors went on to state that any affect the drugs had on cognitive operate and dementia severity at 18 months was “trivial” and that “on functional ability, it is small at best,” as reported by The Pharmaceutical Journal.

“Successful removal of amyloid from the brain does not seem to be associated with clinically meaningful effects in people with mild cognitive impairment or mild dementia due to AD,” the review authors famous.

Richard Oakley, affiliate director of research and innovation at the Alzheimer’s Society, weighed in on the outcomes, saying: “This review’s conclusions make the picture look bleaker than it really is, as authors combined results for a majority of failed drug trials with a small number of more recent successful trials.

“This consists of the trials for lecanemab and donanemab, which the UK medicines regulator agreed deliver a modest but significant benefit for people with early-stage AD.

“It’s essential that we interpret this review with nuance and avoid taking a sledgehammer to decades of pioneering scientific study.”